Suppr超能文献

排卵诱导和宫腔内人工授精后黄体支持的孕激素:系统评价和荟萃分析。

Progesterone luteal support after ovulation induction and intrauterine insemination: a systematic review and meta-analysis.

机构信息

Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.

出版信息

Fertil Steril. 2013 Nov;100(5):1373-80. doi: 10.1016/j.fertnstert.2013.06.034. Epub 2013 Jul 19.

Abstract

OBJECTIVE

To evaluate the effect of luteal phase P support after ovulation induction IUI.

DESIGN

A systematic review and meta-analysis.

SETTING

Not applicable.

PATIENT(S): Undergoing ovulation induction IUI.

INTERVENTION(S): Any form of exogenous P in ovulation induction IUI cycles.

MAIN OUTCOME MEASURE(S): Clinical pregnancy and live birth.

RESULT(S): Five trials were identified that met inclusion criteria and comprised 1,298 patients undergoing 1,938 cycles. Clinical pregnancy (odds ratio [OR] 1.47, 95% confidence interval [CI] 1.15-1.98) and live birth (OR 2.11, 95% CI 1.21-3.67) were more likely in P-supplemented patients. These findings persisted in analyses evaluating per IUI cycle, per patient, and first cycle only data. In subgroup analysis, patients receiving gonadotropins for ovulation induction had the most increase in clinical pregnancy with P support (OR 1.77, 95% CI 1.20-2.6). Conversely, patients receiving clomiphene citrate (CC) for ovulation induction showed no difference in clinical pregnancy with P support (OR 0.89, 95% CI 0.47-1.67).

CONCLUSION(S): Progesterone luteal phase support may be of benefit to patients undergoing ovulation induction with gonadotropins in IUI cycles. Progesterone support did not benefit patients undergoing ovulation induction with CC, suggesting a potential difference in endogenous luteal phase function depending on the method of ovulation induction.

摘要

目的

评估排卵诱导 IUI 后黄体期 P 支持的效果。

设计

系统评价和荟萃分析。

地点

不适用。

患者

接受排卵诱导 IUI。

干预

排卵诱导 IUI 周期中的任何形式的外源性 P。

主要观察指标

临床妊娠和活产。

结果

符合纳入标准的五项试验共纳入 1298 例患者 1938 个周期。接受 P 补充的患者更有可能出现临床妊娠(优势比 [OR] 1.47,95%置信区间 [CI] 1.15-1.98)和活产(OR 2.11,95% CI 1.21-3.67)。这些发现也存在于评估每个 IUI 周期、每个患者和仅第一个周期的数据的分析中。在亚组分析中,接受促性腺激素诱导排卵的患者 P 支持后临床妊娠的增加最为显著(OR 1.77,95% CI 1.20-2.6)。相反,接受枸橼酸氯米酚(CC)诱导排卵的患者 P 支持后临床妊娠无差异(OR 0.89,95% CI 0.47-1.67)。

结论

黄体期 P 支持可能对接受促性腺激素诱导排卵的 IUI 周期患者有益。CC 诱导排卵的患者 P 支持后无临床妊娠获益,提示内源性黄体期功能可能因排卵诱导方法的不同而存在差异。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验